Shares of Moderna, Inc. (NASDAQ:MRNA) have been given an average recommendation of “Hold” by the twenty ratings firms that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, six have given a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $157.94.
Several equities analysts recently commented on the company. Morgan Stanley dropped their target price on Moderna from $215.00 to $201.00 and set an “equal weight” rating on the stock in a report on Thursday, March 4th. Needham & Company LLC lowered Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 9th. Piper Sandler reissued an “overweight” rating and issued a $208.00 target price on shares of Moderna in a report on Monday, March 22nd. SVB Leerink increased their target price on Moderna from $69.00 to $80.00 and gave the company an “underperform” rating in a report on Monday, February 1st. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $139.00 target price on shares of Moderna in a report on Friday, December 11th.
Shares of Moderna stock traded up $1.85 during trading hours on Friday, reaching $133.32. 96,314 shares of the company were exchanged, compared to its average volume of 11,867,124. Moderna has a 1 year low of $31.32 and a 1 year high of $189.26. The stock’s fifty day moving average is $142.99 and its 200 day moving average is $120.18. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.43 and a current ratio of 2.43. The firm has a market cap of $53.40 billion, a PE ratio of -82.43, a PEG ratio of 0.53 and a beta of 1.73.
Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.44). Moderna had a negative return on equity of 28.11% and a negative net margin of 242.73%. The company had revenue of $570.80 million for the quarter, compared to analysts’ expectations of $279.41 million. During the same period in the prior year, the company posted ($0.37) EPS. The firm’s revenue was up 3948.2% compared to the same quarter last year. Research analysts expect that Moderna will post -1.5 earnings per share for the current year.
In other news, CEO Stephane Bancel sold 11,046 shares of the stock in a transaction dated Friday, January 8th. The shares were sold at an average price of $114.02, for a total transaction of $1,259,464.92. Following the completion of the sale, the chief executive officer now owns 6,503,868 shares in the company, valued at $741,571,029.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Tal Zvi Zaks sold 1,199 shares of the stock in a transaction dated Monday, March 22nd. The stock was sold at an average price of $144.82, for a total transaction of $173,639.18. Following the sale, the insider now owns 1,199 shares of the company’s stock, valued at approximately $173,639.18. The disclosure for this sale can be found here. Insiders have sold 5,667,766 shares of company stock valued at $824,359,096 in the last quarter. Insiders own 29.20% of the company’s stock.
A number of large investors have recently made changes to their positions in MRNA. US Bancorp DE lifted its position in Moderna by 17.2% in the third quarter. US Bancorp DE now owns 5,221 shares of the company’s stock valued at $369,000 after purchasing an additional 766 shares during the period. Great West Life Assurance Co. Can lifted its position in Moderna by 87.1% in the third quarter. Great West Life Assurance Co. Can now owns 111,238 shares of the company’s stock valued at $7,687,000 after purchasing an additional 51,784 shares during the period. UBS Asset Management Americas Inc. lifted its position in Moderna by 11.8% in the third quarter. UBS Asset Management Americas Inc. now owns 806,436 shares of the company’s stock valued at $57,055,000 after purchasing an additional 84,951 shares during the period. Cetera Advisor Networks LLC lifted its position in Moderna by 67.4% in the third quarter. Cetera Advisor Networks LLC now owns 12,214 shares of the company’s stock valued at $864,000 after purchasing an additional 4,919 shares during the period. Finally, Cetera Advisors LLC lifted its position in Moderna by 3.4% in the third quarter. Cetera Advisors LLC now owns 12,760 shares of the company’s stock valued at $903,000 after purchasing an additional 418 shares during the period. Hedge funds and other institutional investors own 51.21% of the company’s stock.
Moderna Company Profile
Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.
See Also: How to Invest in Marijuana Stocks
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.